At a big hearing on drug patents, Congress got distracted by small tweaks STAT
Despite their focus on drug prices, lawmakers seemed more eager to talk about peripheral tweaks to the patent system than about fundamental reforms.
At a big hearing on drug patents, Congress got distracted by small tweaks STAT
Despite their focus on drug prices, lawmakers seemed more eager to talk about peripheral tweaks to the patent system than about fundamental reforms.